Axonal Tract Reconstruction Using a Tissue-Engineered Nigrostriatal Pathway in a Rat Model of Parkinson’s Disease

Parkinson’s disease (PD) affects 1–2% of people over 65, causing significant morbidity across a progressive disease course. The classic PD motor deficits are caused by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc), resulting in the loss of their long-distance axonal projections that modulate striatal output. While contemporary treatments temporarily alleviate symptoms of this disconnection, there is no approach able to replace the nigrostriatal pathway. We applied microtissue engineering techniques to create a living, implantable tissue-engineered nigrostriatal pathway (TE-NSP) that mimics the architecture and function of the native pathway. TE-NSPs comprise a discrete population of dopaminergic neurons extending long, bundled axonal tracts within the lumen of hydrogel micro-columns. Neurons were isolated from the ventral mesencephalon of transgenic rats selectively expressing the green fluorescent protein in dopaminergic neurons with subsequent fluorescent-activated cell sorting to enrich a population to 60% purity. The lumen extracellular matrix and growth factors were varied to optimize cytoarchitecture and neurite length, while immunocytochemistry and fast-scan cyclic voltammetry (FSCV) revealed that TE-NSP axons released dopamine and integrated with striatal neurons in vitro. Finally, TE-NSPs were implanted to span the nigrostriatal pathway in a rat PD model with a unilateral 6-hydroxydopamine SNpc lesion. Immunohistochemistry and FSCV established that transplanted TE-NSPs survived, maintained their axonal tract projections, extended dopaminergic neurites into host tissue, and released dopamine in the striatum. This work showed proof of concept that TE-NSPs can reconstruct the nigrostriatal pathway, providing motivation for future studies evaluating potential functional benefits and long-term durability of this strategy. This pathway reconstruction strategy may ultimately replace lost neuroarchitecture and alleviate the cause of motor symptoms for PD patients.

[1]  D. K. Cullen,et al.  Restoring lost nigrostriatal fibers in Parkinson’s disease based on clinically-inspired design criteria , 2021, Brain Research Bulletin.

[2]  D. K. Cullen,et al.  Emerging regenerative medicine and tissue engineering strategies for Parkinson’s disease , 2020, npj Parkinson's Disease.

[3]  D. K. Cullen,et al.  Stretch growth of motor axons in custom mechanobioreactors to generate long‐projecting axonal constructs , 2019, Journal of tissue engineering and regenerative medicine.

[4]  E. Grebenik,et al.  Hydrogel-assisted neuroregeneration approaches towards brain injury therapy: A state-of-the-art review , 2018, Computational and structural biotechnology journal.

[5]  D. K. Cullen,et al.  Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease , 2018, Journal of tissue engineering and regenerative medicine.

[6]  Reuben H. Kraft,et al.  Development of Optically-Controlled “Living Electrodes” with Long-Projecting Axon Tracts for a Synaptic Brain-Machine Interface , 2018 .

[7]  R. Bellamkonda,et al.  Therapeutic efficacy of microtube-embedded chondroitinase ABC in a canine clinical model of spinal cord injury , 2018, Brain : a journal of neurology.

[8]  P. Kaeser,et al.  Dopamine Secretion Is Mediated by Sparse Active Zone-like Release Sites , 2018, Cell.

[9]  Z. Brodnik,et al.  Susceptibility to traumatic stress sensitizes the dopaminergic response to cocaine and increases motivation for cocaine , 2017, Neuropharmacology.

[10]  C. Salafia,et al.  Clarification and 3-D visualization of immunolabeled human placenta villi. , 2017, Placenta.

[11]  S. Cragg,et al.  Striatal dopamine neurotransmission: regulation of release and uptake. , 2016, Basal ganglia.

[12]  D. K. Cullen,et al.  Advanced biomaterial strategies to transplant preformed micro-tissue engineered neural networks into the brain , 2016, Journal of neural engineering.

[13]  D. K. Cullen,et al.  Restoring nervous system structure and function using tissue engineered living scaffolds , 2015, Neural regeneration research.

[14]  M. Stojkovic,et al.  Concise Review: Reactive Astrocytes and Stem Cells in Spinal Cord Injury: Good Guys or Bad Guys? , 2015, Stem cells.

[15]  T. Tierney,et al.  Isolation, culture and long-term maintenance of primary mesencephalic dopaminergic neurons from embryonic rodent brains. , 2015, Journal of visualized experiments : JoVE.

[16]  D. K. Cullen,et al.  Living scaffolds for neuroregeneration. , 2014, Current opinion in solid state & materials science.

[17]  N. Renier,et al.  iDISCO: A Simple, Rapid Method to Immunolabel Large Tissue Samples for Volume Imaging , 2014, Cell.

[18]  Ryan Maloney,et al.  Augmenting protein release from layer-by-layer functionalized agarose hydrogels. , 2014, Carbohydrate polymers.

[19]  D. K. Cullen,et al.  Microtissue engineered constructs with living axons for targeted nervous system reconstruction. , 2012, Tissue engineering. Part A.

[20]  Parastoo Hashemi,et al.  Brain dopamine and serotonin differ in regulation and its consequences , 2012, Proceedings of the National Academy of Sciences.

[21]  Giuseppe Perale,et al.  Sustained Delivery of Chondroitinase ABC from Hydrogel System , 2012, Journal of functional biomaterials.

[22]  D. Surmeier,et al.  Floor plate-derived dopamine neurons from hESCs efficiently engraft in animal models of PD , 2011, Nature.

[23]  Sara R. Jones,et al.  Demon Voltammetry and Analysis software: Analysis of cocaine-induced alterations in dopamine signaling using multiple kinetic measures , 2011, Journal of Neuroscience Methods.

[24]  M. Sofroniew,et al.  Reactive astrocytes as therapeutic targets for CNS disorders , 2010, Neurotherapeutics.

[25]  M. Farrer,et al.  Missing pieces in the Parkinson's disease puzzle , 2010, Nature Medicine.

[26]  Y. Agid,et al.  Long‐term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[27]  Jack J Chen,et al.  Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment. , 2010, The American journal of managed care.

[28]  G. Nikkhah,et al.  Isolation and culture of ventral mesencephalic precursor cells and dopaminergic neurons from rodent brains. , 2009, Current protocols in stem cell biology.

[29]  R. España,et al.  Short-acting cocaine and long-acting GBR-12909 both elicit rapid dopamine uptake inhibition following intravenous delivery , 2008, Neuroscience.

[30]  C. Davie.  A review of Parkinson's disease. , 2008, British medical bulletin.

[31]  P. Zandstra,et al.  Reproducible, Ultra High-Throughput Formation of Multicellular Organization from Single Cell Suspension-Derived Human Embryonic Stem Cell Aggregates , 2008, PloS one.

[32]  D. Chuang,et al.  Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. , 2005, Brain research. Molecular brain research.

[33]  J. Mcdonald,et al.  Controlled release of neurotrophin-3 from fibrin gels for spinal cord injury. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[34]  Garret D Stuber,et al.  Overoxidation of carbon-fiber microelectrodes enhances dopamine adsorption and increases sensitivity. , 2003, The Analyst.

[35]  R. Wightman,et al.  Detecting subsecond dopamine release with fast-scan cyclic voltammetry in vivo. , 2003, Clinical chemistry.

[36]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[37]  J. Steeves,et al.  Suppression of Rho-kinase activity promotes axonal growth on inhibitory CNS substrates , 2003, Molecular and Cellular Neuroscience.

[38]  Andrew J. Lees,et al.  Treatment of Parkinson's disease: levodopa as the first choice , 2002, Journal of Neurology.

[39]  A. Björklund,et al.  Dyskinesias following neural transplantation in Parkinson's disease , 2002, Nature Neuroscience.

[40]  C. Olanow,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[41]  A. Björklund,et al.  Cell replacement therapies for central nervous system disorders , 2000, Nature Neuroscience.

[42]  D. K. Cullen,et al.  Rebuilding Brain Circuitry with Living Micro-Tissue Engineered Neural Networks. , 2015, Tissue engineering. Part A.

[43]  Hyun-Jung Kim.  Stem cell potential in Parkinson's disease and molecular factors for the generation of dopamine neurons. , 2011, Biochimica et biophysica acta.

[44]  A. Tsuji.  Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems , 2011, NeuroRX.

[45]  Hugo Leite-Almeida,et al.  Development and characterization of a novel hybrid tissue engineering-based scaffold for spinal cord injury repair. , 2010, Tissue engineering. Part A.

[46]  M. J. Moore,et al.  Multiple-channel scaffolds to promote spinal cord axon regeneration. , 2006, Biomaterials.

[47]  O. Isacson,et al.  Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells , 2003, Annals of neurology.

[48]  J. Obeso.  Movement disorders , 1998, Stereotactic and functional neurosurgery.